Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Association.

Cardiovascular genetics is a rapidly evolving subspecialty within cardiovascular medicine, and its growth is attributed to advances in genome sequencing and genetic testing and the expanding understanding of the genetic basis of multiple cardiac conditions, including arrhythmias (channelopathies), heart failure (cardiomyopathies), lipid disorders, cardiac complications of neuromuscular conditions, and vascular disease, including aortopathies. There have also been great advances in clinical diagnostic methods, as well as in therapies to ameliorate symptoms, slow progression of disease, and mitigate the risk of adverse outcomes. Emerging challenges include interpretation of genetic test results and the evaluation, counseling, and management of genetically at-risk family members who have inherited pathogenic variants but do not yet manifest disease. With these advances and challenges, there is a need for specialized programs combining both cardiovascular medicine and genetics expertise. The integration of clinical cardiovascular findings, including those obtained from physical examination, imaging, and functional assessment, with genetic information allows for improved diagnosis, prognostication, and cascade family testing to identify and to manage risk, and in some cases to provide genotype-specific therapy. This emerging subspecialty may ultimately require a new cardiovascular subspecialist, the genetic cardiologist, equipped with these combined skills, to permit interpretation of genetic variation within the context of phenotype and to extend the utility of genetic testing. This scientific statement outlines current best practices for delivering cardiovascular genetic evaluation and care in both the pediatric and the adult settings, with a focus on team member expertise and conditions that most benefit from genetic evaluation.

[1]  K. Ormond,et al.  Mindfulness Among Genetic Counselors Is Associated with Increased Empathy and Work Engagement and Decreased Burnout and Compassion Fatigue , 2018, Journal of Genetic Counseling.

[2]  E. Ashley,et al.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.

[3]  D. Ledbetter,et al.  Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. , 2018, Journal of the American College of Cardiology.

[4]  R. Finkel,et al.  Genetic therapies for inherited neuromuscular disorders. , 2018, The Lancet. Child & adolescent health.

[5]  Megan E. Grove,et al.  Clinical Cardiovascular Genetic Counselors Take a Leading Role in Team-based Variant Classification , 2018, Journal of Genetic Counseling.

[6]  P. Ridker,et al.  Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. , 2018, Journal of clinical lipidology.

[7]  D. Judge,et al.  Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[8]  E. Ashley,et al.  Cardiovascular Precision Medicine in the Genomics Era , 2018, JACC. Basic to translational science.

[9]  S M Caspar,et al.  Clinical sequencing: From raw data to diagnosis with lifetime value , 2018, Clinical genetics.

[10]  K. Yoneyama,et al.  Cardiovascular magnetic resonance imaging in heart failure , 2018, Expert review of cardiovascular therapy.

[11]  Katherine Payne,et al.  Cost-effectiveness analyses of genetic and genomic diagnostic tests , 2018, Nature Reviews Genetics.

[12]  J. van Lennep,et al.  Monogenetic disorders of the cholesterol metabolism and premature cardiovascular disease , 2017, European journal of pharmacology.

[13]  J. Shendure,et al.  DNA sequencing at 40: past, present and future , 2017, Nature.

[14]  D. Tester,et al.  Genomic Triangulation and Coverage Analysis in Whole-Exome Sequencing–Based Molecular Autopsies , 2017, Circulation. Cardiovascular genetics.

[15]  E. Ashley,et al.  Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation , 2017, Circulation. Cardiovascular genetics.

[16]  E. Mercuri,et al.  Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues , 2017, Nucleic acid therapeutics.

[17]  Paul J. Wang,et al.  Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. , 2017, Circulation.

[18]  L. Mestroni,et al.  Dilated Cardiomyopathy: Genetic Determinants and Mechanisms , 2017, Circulation research.

[19]  K. Shah,et al.  Transthyretin Cardiac Amyloidosis , 2017, Current Cardiology Reports.

[20]  A. Wilde,et al.  Channelopathies, genetic testing and risk stratification. , 2017, International journal of cardiology.

[21]  Toshihiro Tanaka,et al.  Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome: A Japanese Multicenter Registry , 2017, Circulation.

[22]  Leon Axel,et al.  Recent Advances in Cardiovascular Magnetic Resonance: Techniques and Applications , 2017, Circulation. Cardiovascular imaging.

[23]  Rahul C. Deo,et al.  Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease. , 2017, Cell stem cell.

[24]  Claudia Stöllberger,et al.  Left ventricular noncompaction cardiomyopathy: cardiac, neuromuscular, and genetic factors , 2017, Nature Reviews Cardiology.

[25]  U. Landmesser,et al.  Restrictive cardiomyopathy , 2017, Wiener klinische Wochenschrift.

[26]  Soma Das,et al.  Clinical Laboratories Collaborate to Resolve Differences in Variant Interpretations Submitted to ClinVar , 2017, Genetics in Medicine.

[27]  G. Tomaselli,et al.  Left Ventricular Dysfunction and Conduction Disturbances in Patients With Myotonic Muscular Dystrophy Type I and II , 2017, JAMA cardiology.

[28]  A. Dubuc,et al.  The current state of clinical interpretation of sequence variants. , 2017, Current opinion in genetics & development.

[29]  M. Link,et al.  Arrhythmogenic Right Ventricular Cardiomyopathy. , 2017, The New England journal of medicine.

[30]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[31]  M. Perez,et al.  Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association , 2016, Circulation. Cardiovascular genetics.

[32]  Hongfang Liu,et al.  Rapid identification of familial hypercholesterolemia from electronic health records: The SEARCH study. , 2016, Journal of clinical lipidology.

[33]  Robert C. Green,et al.  Erratum: Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium (American Journal of Human Genetics (2016) 98(6) (1067–1076) (S0002929716300593) (10.1016/j.ajhg.2016.03.024)) , 2016 .

[34]  J. Skinner,et al.  A Prospective Study of Sudden Cardiac Death among Children and Young Adults. , 2016, The New England journal of medicine.

[35]  C. Eng,et al.  Assessment of clinical workload for general and specialty genetic counsellors at an academic medical center: a tool for evaluating genetic counselling practices , 2016, npj Genomic Medicine.

[36]  C. Caleshu,et al.  A Case for Inclusion of Genetic Counselors in Cardiac Care , 2016, Cardiology in review.

[37]  Christine E. Seidman,et al.  A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice , 2016, Science.

[38]  C. Autore,et al.  Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy , 2016, Heart.

[39]  D. Milewicz,et al.  Precision medical and surgical management for thoracic aortic aneurysms and acute aortic dissections based on the causative mutant gene. , 2016, The Journal of cardiovascular surgery.

[40]  Matthew K Ito,et al.  The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. , 2015, Circulation.

[41]  J. Brugada,et al.  Genetics of inherited arrhythmias in pediatrics , 2015, Current opinion in pediatrics.

[42]  M. Ackerman,et al.  Genetic purgatory and the cardiac channelopathies: Exposing the variants of uncertain/unknown significance issue. , 2015, Heart rhythm.

[43]  P. Elliott,et al.  Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy , 2015, Circulation. Heart failure.

[44]  R. Hershberger,et al.  Dilated Cardiomyopathy Overview , 2015 .

[45]  L. Adès,et al.  The Cardiac Genetics Clinic: a model for multidisciplinary genomic medicine , 2015, The Medical journal of Australia.

[46]  P. Schwartz,et al.  Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. , 2015, Circulation.

[47]  A. Wilde,et al.  Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. , 2015, European heart journal.

[48]  J. Borén,et al.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment , 2015, European heart journal.

[49]  E. Ashley,et al.  Future Translational Applications From the Contemporary Genomics Era: A Scientific Statement From the American Heart Association , 2015, Circulation.

[50]  E. Hoffman,et al.  Contemporary Cardiac Issues in Duchenne Muscular Dystrophy , 2015, Circulation.

[51]  E. Ashley,et al.  Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. , 2015, JACC. Heart failure.

[52]  B. Maron,et al.  New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[53]  Emily C. O'Brien,et al.  INITIAL RESULTS FROM THE CASCADE-FH REGISTRY: CASCADE SCREENING FOR AWARENESS AND DETECTION OF FAMILIAL HYPERCHOLESTEROLEMIA , 2015 .

[54]  Virginie Beauséjour Ladouceur Training in cardiovascular genetics. , 2015 .

[55]  M. Fornage,et al.  Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. , 2015, Circulation. Cardiovascular genetics.

[56]  D. Gaudet,et al.  Targeting APOC3 in the familial chylomicronemia syndrome. , 2014, The New England journal of medicine.

[57]  Lorenzo L. Pesce,et al.  Targeted Analysis of Whole Genome Sequence Data to Diagnose Genetic Cardiomyopathy , 2014, Circulation. Cardiovascular genetics.

[58]  A. Anastasakis,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[59]  Anya E. R. Prince,et al.  Genetic Information, Non-Discrimination, and Privacy Protections in Genetic Counseling Practice , 2014, Journal of Genetic Counseling.

[60]  C. Semsarian,et al.  Conveying a probabilistic genetic test result to families with an inherited heart disease. , 2014, Heart rhythm.

[61]  S. Ware,et al.  Provision of Cardiovascular Genetic Counseling Services: Current Practice and Future Directions , 2014, Journal of Genetic Counseling.

[62]  Emily C. O'Brien,et al.  Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. , 2014, American heart journal.

[63]  David M Herrington,et al.  Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. , 2013, Circulation.

[64]  C. Tracy,et al.  HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. , 2013, Heart rhythm.

[65]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[66]  A. Tajik,et al.  Aortopathies: etiologies, genetics, differential diagnosis, prognosis and management. , 2013, The American journal of medicine.

[67]  M. Friedberg,et al.  Speckle Tracking Echocardiography in Pediatric and Congenital Heart Disease , 2013, Echocardiography.

[68]  S. Ware,et al.  Uptake of Cardiac Screening and Genetic Testing Among Hypertrophic and Dilated Cardiomyopathy Families , 2013, Journal of Genetic Counseling.

[69]  R. Lucariello,et al.  Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC/D): A Systematic Literature Review , 2013, Clinical Medicine Insights. Cardiology.

[70]  W. Groh Arrhythmias in the muscular dystrophies. , 2012, Heart rhythm.

[71]  Donald Wolfgeher,et al.  Population-Based Variation in Cardiomyopathy Genes , 2012, Circulation. Cardiovascular genetics.

[72]  J. Elefteriades,et al.  Natural history of thoracic aortic aneurysms. , 2012, Journal of vascular surgery.

[73]  E. Ashley,et al.  Genetics and Cardiovascular Disease: A Policy Statement From the American Heart Association , 2012, Circulation.

[74]  G. Sutherland,et al.  The Heart in Friedreich Ataxia: Definition of Cardiomyopathy, Disease Severity, and Correlation With Neurological Symptoms , 2012, Circulation.

[75]  L. Mestroni,et al.  Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.

[76]  Udo Hoffmann,et al.  A Genetic Risk Score Is Associated With Incident Cardiovascular Disease and Coronary Artery Calcium: The Framingham Heart Study , 2012, Circulation. Cardiovascular genetics.

[77]  L. Yeates,et al.  The emerging role of the cardiac genetic counselor. , 2011, Heart rhythm.

[78]  D. Fatkin,et al.  Guidelines for genetic testing of inherited cardiac disorders. , 2011, Heart, lung & circulation.

[79]  Y. Oade,et al.  Arrhythmogenic right ventricular cardiomyopathy , 2011, BMJ Case Reports.

[80]  H. Calkins,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Heart rhythm.

[81]  R. Hershberger,et al.  Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. , 2011, Journal of the American College of Cardiology.

[82]  D. Tester,et al.  Genetic Testing for Potentially Lethal, Highly Treatable Inherited Cardiomyopathies/Channelopathies in Clinical Practice , 2011, Circulation.

[83]  L. Peltonen,et al.  Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland , 2011, European Journal of Human Genetics.

[84]  J. Healey,et al.  Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. , 2011, The Canadian journal of cardiology.

[85]  S. Day,et al.  Psychological Issues in Genetic Testing for Inherited Cardiovascular Diseases , 2011, Circulation. Cardiovascular genetics.

[86]  A. Keren,et al.  Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2010, European heart journal.

[87]  B. Maron Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[88]  M. Maron,et al.  Survival After Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[89]  Y. Pinto,et al.  Hereditary muscular dystrophies and the heart , 2010, Neuromuscular Disorders.

[90]  H. Tan,et al.  Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? , 2010, Journal of the American College of Cardiology.

[91]  D. Judge Use of genetics in the clinical evaluation of cardiomyopathy. , 2009, JAMA.

[92]  M. P. van den Berg,et al.  Family letters are an effective way to inform relatives about inherited cardiac disease , 2009, American journal of medical genetics. Part A.

[93]  L. Mestroni,et al.  Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. , 2009, Journal of cardiac failure.

[94]  R. Hershberger,et al.  Genetic testing and genetic counseling in cardiovascular genetic medicine: overview and preliminary recommendations. , 2008, Congestive heart failure.

[95]  Timothy B Sackton,et al.  Mutations in smooth muscle α-actin (ACTA2) lead to thoracic aortic aneurysms and dissections , 2007, Nature Genetics.

[96]  S. Priori,et al.  Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients , 2007, Circulation.

[97]  D. Srivastava,et al.  Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. , 2007, Circulation.

[98]  P. Byers,et al.  Aneurysm syndromes caused by mutations in the TGF-beta receptor. , 2006, The New England journal of medicine.

[99]  E. Gronda,et al.  Rationale and process: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[100]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[101]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[102]  R. Bennett,et al.  A New Definition of Genetic Counseling: National Society of Genetic Counselors’ Task Force Report , 2006, Journal of Genetic Counseling.

[103]  D. Judge,et al.  Marfan's syndrome , 2005, The Lancet.

[104]  Christine E Seidman,et al.  The genetic basis for cardiac remodeling. , 2005, Annual review of genomics and human genetics.

[105]  R. Hershberger,et al.  Clinical and genetic issues in familial dilated cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[106]  S. Priori,et al.  Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome , 2004, Circulation.

[107]  S. Humphries,et al.  Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study , 2000, BMJ : British Medical Journal.

[108]  Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults: Echocardiographic Analysis of 4111 Subjects in the Cardia Study , 1996 .

[109]  R. Hegele,et al.  Apolipoprotein E in Hyperlipidemia , 1994, Annals of Internal Medicine.

[110]  A. Motulsky,et al.  Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. , 1973, The Journal of clinical investigation.

[111]  Sandeep Krishnamurthy University of Washington , 2020, The Grants Register 2021.

[112]  K. Musunuru,et al.  CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia. , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[113]  D. Judge,et al.  Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. , 2018, Journal of cardiac failure.

[114]  J. Haas,et al.  Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals , 2017, Clinical Research in Cardiology.

[115]  R. Hegele,et al.  Familial hypercholesterolaemia , 2017, Nature Reviews Disease Primers.

[116]  Matthew S. Lebo,et al.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.

[117]  Virginie Beauséjour Ladouceur Training in cardiovascular genetics. , 2015, Journal of the American College of Cardiology.

[118]  R. Hegele,et al.  Genetics 101 for cardiologists: rare genetic variants and monogenic cardiovascular disease. , 2013, The Canadian journal of cardiology.

[119]  Ferhaan Ahmad,et al.  Towards Systems Biology of Pulmonary Hypertension , 2012 .

[120]  H. Watkins,et al.  Inherited cardiomyopathies. , 2011, The New England journal of medicine.

[121]  H. Heidbüchel,et al.  PEDIATRIC AND CONGENITAL HEART DISEASE , 2010 .

[122]  R. Hatala,et al.  Arrhythmogenic right ventricular cardiomyopathy/dysplasia. , 2005, Bratislavske lekarske listy.

[123]  H. Crijns,et al.  Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? , 2004, Journal of Molecular Medicine.